Celecoxib does not appear to affect prosthesis fixation in total knee replacement

Figures & data

Table 1. Patient characteristics

	Placebo (n = 25)	Celecoxib (n = 25)
Sex, M/F	14/11	8/17
Age, years (SD)	69 (8)	68 (6)
Time of surgery, min (SD)	87 (11)	80 (9)

Figure 1. MTPM during follow-up, median (line) with interquartile range (boxes) and non-outliers range (whiskers), placebo, celecoxib, outliers (values, 1,5-3-fold larger than the interquartile range), * extremes (values > 3-fold larger than the interquartile range).

Figure 2. MTPM between 1 and 2 years.

Table 2. MTPM (mm) and segment motion (rotation in degrees and translation in mm) at 2 years

	Placebo		Celecoxib		95% CI		Levene’s test
	mean	SD	mean	SD	Min.	Max.	p-value
MTPM	0.40	0.15	0.35	0.17	–0.15	0.04	0.56
Rotation x (anterior–posterior tilt)	–0.24	0.24	–0.14	0.16	–0.02	0.22	0.10
Rotation y (inward–outward rotation)	–0.01	0.18	–0.01	0.17	–0.11	0.09	0.40
Rotation z (varus-valgus tilt)	0.01	0.15	0.00	0.12	–0.09	0.06	0.43
Translation x (medial–lateral translation)	0.00	0.05	0.00	0.06	–0.02	0.04	0.17
Translation y (subsidence – lift-off)	–0.01	0.12	0.01	0.13	–0.05	0.09	0.94
Translation z (anterior–posterior translation)	0.01	0.07	0.04	0.09	–0.01	0.08	0.27

Figure 3. Pain during follow-up (median with interquartile range): placebo, celecoxib.

Figure 4. Development of range of motion during follow-up (mean ± SD): extension placebo, flexion placebo, extension celecoxib, flexion celecoxib.

Figure 5. Mean KOOS values before and 2 years after TKR: placebo at baseline, celecoxib at baseline, placebo at 2 years, celecoxib at 2 years.